||Salirasib(Ki=2.6 μM), an effective competitive prenylated protein methyltransferase (PPMTase) inhibitor, inhibits Ras methylation with potential antineoplastic activity.
||Lonafarnib is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B, and N-ras (IC50: 1.9/5.2/2.8 nM).
||ML-098 is an activator of the GTP-binding protein Rab7 (EC50: 77.6 nM).
||Antineoplaston A10 is a naturally occurring substance and the first antineoplaston in the human body to be chemically identified. It displayed anti-proliferative action inhibiting
||Antineoplaston A 10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.
||AMG-510 is a potent KRAS G12C covalent inhibitor, treatment with AMG 510 led to the regression of KRASG12C tumours and improved the anti-tumour efficacy of chemotherapy and targete
||6H05 is a selective, and allosteric oncogenic mutant K-Ras(G12C) inhibitor.
||ARS-1620 is a covalent inhibitor of K-RASG12C.
||CID-1067700 is one of the first identified competitive inhibitors of nucleotide binding by Ras-related GTPases（Rab7 with a Ki of 13 nM).
||Oncrasin 1 is a potent inhibitor of anticancer that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations
||MRTX849 is a potent, selective, and covalent KRASG12C inhibitor with potential antineoplastic activity.selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits K
||PROTAC K-Ras Degrader-1
||PROTAC K-Ras Degrader-1 is potent degrader of K-Ras based PROTAC.
||ARS-1323 (the racemate of ARS-1620) is a mutant K-ras G12C inhibitor extracted from patent WO 2015054572 A1.
||ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.
||ARS-1630 is a mutant K-ras G12C inhibitor extracted from patent WO 2015054572 A1. It is a less active enantiomer of ARS-1620.
||BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 of 6 nM),with anticancer activity.
||BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) with nanomolar affinity. BI-2852 is leading to inhibition of downstream signaling and an antiproliferative eff
||KB-5246, displays antibacterial activities.is a tetracyclic quinolone.
||MC 976 is a derivative of Vitamin D3.
||KRAS G12C inhibitor 13
||KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .
||KRAS G12C inhibitor 14
||KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor .
||KRAS G12C inhibitor 15
||KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .
||KRAS G12C inhibitor 16
||KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.
||KRAS G12C inhibitor 17
||KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.
||KRAS inhibitor-6 is a potent KRAS G12C inhibitor.
||KRAS inhibitor-7 is a potent KRAS G12C inhibitor.
||KRAS inhibitor-8 is a potent KRAS G12C inhibitor.
||KRas G12C inhibitor 1
||KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.
||KRas G12C inhibitor 2
||KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.
||KRas G12C inhibitor 3
||KRas G12C inhibitor 3 is a compound that inhibits KRas G12C.
||KRas G12C inhibitor 4
||KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.
||KRAS G12C inhibitor 5
||KRAS G12C inhibitor 5 is a KRas G12C inhibitor.
||AMG-510 is a selective and orally bioavailable KRAS G12C covalent inhibitor.